therapy for “early mf”: pros and cons
Published 8 years ago • 658 plays • Length 23:20Download video MP4
Download video MP3
Similar videos
-
19:54
therapy for “early myelofibrosis”: pros and cons
-
18:09
diagnosis, prognosis, and therapy of true et vs. prefibrotic mf
-
10:33
debate: should we treat early-stage myelofibrosis? - no, only observe
-
12:00
debate: should we treat early-stage myelofibrosis? - yes, initiate therapy
-
20:30
my approach to mf management
-
20:03
my approach to mf management
-
19:52
treatment option for cytopenic myelofibrosis (mf)
-
25:15
how to manage side effects of jak inhibitors for mylofibrosis in the clinical practice
-
21:55
a unified approach to lower risk mds: standard and emerging therapies
-
19:11
novel agents and combination therapies in myelofibrosis
-
29:27
my view on current and future use of jak inhibitors for et, pv, and mf
-
19:23
novel agents and combination therapies in myelofibrosis
-
19:03
assessment of novel treatment options for patients with pv
-
19:04
my view on current and future use of jak inhibitors for et, pv, and mf
-
17:02
indication for cytoreductive therapy in et and pv: do we have it right?
-
16:10
stem cell transplant for myelofibrosis in the jak2 inhibitor era
-
23:17
mutations in myelofibrosis: which to test for, when and why
-
21:52
stem cell transplant for myelofibrosis in the jak2 inhibitor era
-
46:19
the evolving role of doacs in the management of venous and arterial disease